Atopic Dermatitis

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

A pediatric dermatologist discusses dupilumab for pediatric atopic dermatitis in addition to promising new therapies.

Lisa Swanson, MD, and Brad Glick, DO, FAAD, discuss a wide range of dermatological conditions faced by pediatric patients—from acne to atopic dermatitis, and everything in between.

Brad Glick gives an overview of new and exciting trends in the field of dermatology.

FDA application is based on the positive data from 3 recent phase 3 clinical trials.

Though atopic dermatitis is a relatively common condition, most of the existing scientific literature has ignored the majority of patients who have mild or limited disease.

New research suggests the Janus kinase 1 and 2 inhibitor relieves symptoms of atopic dermatitis at a daily dose of 4 mg.

Newly published data show routine testing is unlikely to change the management of patients with CSU.

D. farinae and D. pteronyssinus positive skin prick test results were much more frequent in patients >18 years.

Patients impacted by pruritus were more depressed and anxious than a comparison control group.

More trials must include older patients in order to better understand the safety and efficacy of systemic treatments for atopic dermatitis.

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.

An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.

The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.

Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.

Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.

Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.